Study to Evaluate the Effect of GBT440 on TCD in Pediatrics With Sickle Cell Disease

Summary

This study is a Phase 3, randomized, double-blind, placebo-controlled study of voxelotor in pediatric participants, aged ≥ 2 to \< 15 years old, with Sickle Cell Disease. The primary objective is to evaluate the effect of voxelotor on the TCD (Transcranial Doppler Ultrasound) measurements in SCD participants in this age range.

Timeline

Start

2020-11-11

Primary completion

2024-01-18

Completion

2024-11-06

Drugs

Indications